Arvinas (ARVN) Cash & Current Investments (2017 - 2026)
Arvinas (ARVN) recorded quarterly Cash & Current Investments of $614.9 million in Q1 2026, down 10.29% quarter-over-quarter from $685.4 million in Q4 2025, and down 35.57% on a YoY basis from $954.3 million in Q1 2025.
Arvinas (ARVN) Cash & Current Investments (2017 - 2026) Analysis & Trends
Arvinas' Cash & Current Investments history runs 10 years deep, the most recent figure standing at $614.9 million for Q1 2026.
- In Q1 2026, Cash & Current Investments fell 35.57% year-over-year to $614.9 million; the TTM figure through Mar 2026 stood at $614.9 million (down 35.57% YoY), while the FY2025 annual figure was $685.4 million, down 34.06% from the prior year.
- Cash & Current Investments was $614.9 million for Q1 2026 at Arvinas, down from $685.4 million in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $1.3 billion in Q4 2023 to a low of $66.8 million in Q1 2022.
- Historically, Cash & Current Investments has averaged $552.2 million across 5 years, with a median of $614.9 million in 2026.
- The sharpest annual moves came in 2022 and 2023: Cash & Current Investments sank 89.74% in 2022, then surged 1352.76% in 2023.
- A 5-year view of Cash & Current Investments shows it stood at $86.8 million in 2022, then soared by 1352.76% to $1.3 billion in 2023, then decreased by 17.57% to $1.0 billion in 2024, then plunged by 34.06% to $685.4 million in 2025, then retreated by 10.29% to $614.9 million in 2026.
- The last three Cash & Current Investments figures came in at $614.9 million (Q1 2026), $685.4 million (Q4 2025), and $787.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 32.30 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 2.13 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 286.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 18.44 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 2.77 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 7.20 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 7.25 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Arvinas | 492.16 Mn | -122.74 Mn | - | 614.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 614.90 Mn |
| Dec 31, 2025 | 685.40 Mn |
| Sep 30, 2025 | 787.60 Mn |
| Jun 30, 2025 | 861.20 Mn |
| Mar 31, 2025 | 954.30 Mn |
| Dec 31, 2024 | 1.04 Bn |
| Sep 30, 2024 | 1.12 Bn |
| Jun 30, 2024 | 1.23 Bn |
| Mar 31, 2024 | 93.50 Mn |
| Dec 31, 2023 | 1.26 Bn |
| Sep 30, 2023 | 119.20 Mn |
| Jun 30, 2023 | 96.10 Mn |
| Mar 31, 2023 | 135.70 Mn |
| Dec 31, 2022 | 86.80 Mn |
| Sep 30, 2022 | 138.10 Mn |
| Jun 30, 2022 | 97.70 Mn |
| Mar 31, 2022 | 66.80 Mn |
| Dec 31, 2021 | 112.80 Mn |
| Sep 30, 2021 | 260.16 Mn |
| Jun 30, 2021 | 600.58 Mn |